Search papers, labs, and topics across Lattice.
This study extends the empirical Bayes variational autoencoder (EB-VAE) framework to effectively model longitudinal tumor measurements and time-to-event data, addressing the challenge of integrating diverse data sources in cancer treatment response analysis. By employing a hybrid decoder that incorporates a hazard model, the framework successfully predicts tumor growth and dropout times while leveraging genetic covariates for enhanced individual-level predictions. The results indicate that the EB-VAE framework not only aligns with established nonlinear mixed-effects estimates but also identifies significant genetic indicators relevant to treatment outcomes in melanoma and breast cancer.
Joint modeling of tumor growth and dropout using EB-VAE reveals critical genetic indicators that could transform personalized cancer treatment strategies.
Longitudinal tumor measurements, dropout information, and genetic covariates provide complementary information about treatment response, but integrating these data sources within a single population modeling framework remains challenging. We extend the empirical Bayes variational autoencoder (EB-VAE) framework to joint longitudinal and time-to-event modeling and evaluate it on tumor growth data. The framework represents inter-individual variability using latent individual effects regularized by a covariate-conditioned empirical Bayes prior, while a decoder maps these latent effects to tumor-volume trajectories. To account for informative dropout, the decoder was augmented with a hazard model, yielding joint predictions of tumor growth and time to dropout. We further compared fully neural and hybrid semi-mechanistic decoder formulations and incorporated genomic covariates through a genetics-conditioned prior adaptation. The hybrid decoder recovered treatment-effect parameters broadly consistent with previously reported nonlinear mixed-effects estimates, while achieving prior predictive performance comparable to the neural decoder. The joint model reproduced both tumor-volume distributions and dropout patterns in held-out individuals, and genetic conditioning improved individual-level prior predictions in both cutaneous melanoma and breast cancer experiments. Stability selection identified several biologically plausible genetic indicators, including alterations in BRAF, NRAS, NF1, and MDM2. These results demonstrate that EB-VAE provides a flexible probabilistic framework for combining neural dynamics, mechanistic structure, time-to-event modeling, and high-dimensional covariates in pharmacometric applications.
